Alpha 2.0
Login Register
» Authors » Isabelle Solassol

Isabelle Solassol

Explore the profile of Isabelle Solassol including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 110
Followers 0
Related Specialties
Chemistry
Biochemistry
Oncology
Top 10 Co-Authors
Frederic Pinguet
Francoise M M Bressolle
Pierre-Antoine Bonnet
Jerome Solassol
Carine Deleuze-Masquefa
Sonia Khier
Francoise Bressolle
Julie A Vendrell
Stephane Culine
Georges Moarbess
Published In
Ther Drug Monit
Clin Chem
Eur J Pharm Sci
Expert Rev Proteomics
Int J Mol Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
An optimized NGS Protocol for Detecting De Novo MET Amplification in NSCLC: Prognostic and Therapeutic Implications
Cabello-Aguilar S, Vendrell J, Evrard S, Thomas Q, Roch B, Escudie F, et al.
Lab Invest . 2025 Feb; :104117. PMID: 39986540
MET amplification (MET) is a noteworthy genomic alteration that can occur in patients with non-small cell lung cancer (NSCLC). It has been demonstrated to occur as a primary oncogenic driver...
2.
Differential Sensitivity of Germline and Somatic Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
Vendrell J, Ban I, Solassol I, Audran P, Cabello-Aguilar S, Topart D, et al.
Int J Mol Sci . 2023 Sep; 24(18). PMID: 37762485
Purpose: The introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of testing worldwide. In this study, we aim...
3.
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
Vendrell J, Quantin X, Aussel A, Solassol I, Serre I, Solassol J
Transl Lung Cancer Res . 2022 Jan; 10(11):4084-4094. PMID: 35004240
Background: Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is highly selective for subclones in patients with non-small cell lung cancer (NSCLC). Unfortunately, all patients...
4.
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced -Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Solassol I, Pinguet F, Quantin X
Biomolecules . 2019 Nov; 9(11). PMID: 31671561
Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized...
5.
Protein interactions study through proximity-labeling
Beganton B, Solassol I, Mange A, Solassol J
Expert Rev Proteomics . 2019 Jul; 16(8):717-726. PMID: 31269821
: The proteome is a dynamic system in which protein-protein interactions play a crucial part in shaping the cell phenotype. However, given the current limitations of available technologies to describe...
6.
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry
Lafaille F, Solassol I, Enjalbal C, Bertrand B, Doulain P, Vappiani J, et al.
J Pharm Biomed Anal . 2013 Nov; 88:429-40. PMID: 24176748
EAPB0503, belonging to the imidazo[1,2-a]quinoxaline series, is an anticancer drug with antitumoral activity against a variety of tumors. Previous studies have shown that this drug undergoes demethylation and oxygenation reactions....
7.
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas
Khier S, Gattacceca F, El Messaoudi S, Lafaille F, Deleuze-Masquefa C, Bompart J, et al.
Drug Metab Dispos . 2010 Jul; 38(10):1836-47. PMID: 20660102
For several years, our group has been developing quinoxalinic compounds. Two of them, N-methyl-1-(2-phenethyl)imidazo[1,2-a]quinoxalin-4-amine (EAPB0203) and 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503), have emerged as the most promising anticancer drugs. In the present work,...
8.
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma
Khier S, Deleuze-Masquefa C, Moarbess G, Gattacceca F, Margout D, Solassol I, et al.
Eur J Pharm Sci . 2009 Oct; 39(1-3):23-9. PMID: 19854270
In spite of the development of new anticancer drugs by the pharmaceutical industry, melanoma and T lymphomas are diseases for which medical advances remain limited. Thus, there was an urgent...
9.
Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model
Charasson V, Hillaire-Buys D, Solassol I, Laurand-Quancard A, Pinguet F, Le Morvan V, et al.
Eur J Cancer . 2009 Jun; 45(13):2391-401. PMID: 19501504
Folate, a vitamin of the B group involved in one-carbon group metabolism, plays an important role in DNA synthesis and methylation. Several polymorphisms in the genes involved in folate uptake...
10.
Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS
Khier S, Moarbess G, Deleuze-Masquefa C, Solassol I, Margout D, Pinguet F, et al.
J Sep Sci . 2009 Apr; 32(9):1363-73. PMID: 19399864
Since several years, our group developed quinoxalinic compounds. Among the synthesized compounds, in the imidazo[1,2-a]quinoxaline series, EAPB0203 has shown interesting activities both on melanoma and lymphoma. The structure of EAPB0203...